Clinical trial · no report yet · Phase 3
NCT02193282
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
- NCT02193282 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Clinical Observation; Erlotinib Hydrochloride; Laboratory Biomarker Analysis; Placebo Administration
- Arms
- Arm A (blinded erlotinib hydrochloride) · Experimental
- Arm B (placebo) · Placebo comparator
- Arm C (unblinded erlotinib hydrochloride) · Experimental
- Arm D (observation) · Active comparator
- Enrollment
- 390
- Primary outcomes
- Overall survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Feb 11, 2015
- Primary completion
- Dec 6, 2025
- Results posted
- No
- Registry record
- NCT02193282 · updated Jul 2, 2026